Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator
暂无分享,去创建一个
Oscar Casis | Michael C Sanguinetti | M. Sanguinetti | S. Olesen | O. Casis | Søren-Peter Olesen | Ó. Casis
[1] Michael C Sanguinetti,et al. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. , 2003, Molecular pharmacology.
[2] W. Stühmer,et al. Electrophysiological recording from Xenopus oocytes. , 1992, Methods in enzymology.
[3] M. Sanguinetti,et al. A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. , 1998, Molecular pharmacology.
[4] M. Sanguinetti,et al. Fast inactivation causes rectification of the IKr channel , 1996, The Journal of general physiology.
[5] G. Breithardt,et al. Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .
[6] Robert Pearlstein,et al. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.
[7] S. Priori,et al. The long QT syndrome. , 1997, Current problems in cardiology.
[8] Jiesheng Kang,et al. Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel , 2005, Molecular Pharmacology.
[9] Gregory W. Kauffman,et al. Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.
[10] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[11] Michael C Sanguinetti,et al. Molecular Determinants of Voltage-dependent Human Ether-a-Go-Go Related Gene (HERG) K+ Channel Block* , 2002, The Journal of Biological Chemistry.
[12] Bertram Pitt,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.
[13] Robert F Gilmour,et al. Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes. , 2004, American journal of physiology. Heart and circulatory physiology.
[14] M. Sanguinetti,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[15] K. Lawson,et al. Potassium channel openers as potential therapeutic weapons in ion channel disease. , 2000, Kidney international.
[16] Jun Zhou,et al. Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity , 2005, Molecular Pharmacology.
[17] M. Sanguinetti,et al. A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation , 1998, The Journal of physiology.
[18] Y. P. Adams,et al. MECHANISMS AND MANAGEMENT , 1998 .
[19] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[20] G. Sarkar,et al. The "megaprimer" method of site-directed mutagenesis. , 1990, BioTechniques.
[21] H. Duff,et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.
[22] C Antzelevitch,et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.
[23] M. Sanguinetti,et al. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[24] A. Keren,et al. Magnesium therapy for torsades de pointes. , 1984, The American journal of cardiology.
[25] P. Schraeder,et al. Stress and sudden death , 2006, Epilepsy & Behavior.
[26] R. Martínez,et al. Torsades de pointes: atypical rhythm, atypical treatment. , 1987, Annals of emergency medicine.
[27] Robert F Gilmour,et al. Contribution of IKr to Rate-Dependent Action Potential Dynamics in Canine Endocardium , 2004, Circulation research.
[28] M. Sanguinetti,et al. Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.
[29] A. Moss,et al. Stress and sudden death. The case of the long QT syndrome. , 1991, Circulation.
[30] M. Sanguinetti,et al. Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels , 2003, Circulation research.
[31] U. Ravens,et al. Activation of Human ether-a-go-go-Related Gene Potassium Channels by the Diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) , 2006, Molecular Pharmacology.
[32] A. Camm,et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.
[33] P. Schwartz,et al. Torsade de pointes. Mechanisms and management. , 1994, Drugs.
[34] Gary Yellen,et al. The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.